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ABSTRACT
The formation of hepatic metastases in colorectal cancer is the main
cause of patient death. Current therapies directed at hepatic metastasis of
colorectal cancer have had minimal impact on outcome. Therefore, alter-
native treatment strategies for liver metastasis require development. The
present study was performed to evaluate the application of cDNA of LK68
encoding apolipoprotein(a) kringles IV-9, IV-10, and V as possible candi-
dates for gene therapy treatment of this life-threatening disease. The
murine colorectal cancer cell line CT26 was transduced ex vivo with LK68
cDNA via retroviral gene transfer, and an experimental model of hepatic
metastasis was established by injecting LK68-expressing and control cells
into the spleens of BALB/c mice. Expression of LK68 did not affect the
growth characteristics and viability of transduced CT26 cells in vitro.
LK68 produced from CT26 cells substantially inhibited the migration of
endothelial cells in vitro. In vivo, substantial suppression of liver metastasis
and prolonged survival were observed in mice bearing LK68-expressing
CT26 cells, compared with controls. LK68-expressing liver metastases
were restricted to smaller sizes and displayed decreased microvessel den-
sity and increased tumor cell apoptosis. Our data collectively indicate that
LK68 suppresses angiogenesis-dependent progression of prevascular mi-
crometastases to macroscopic tumors and their growth, which are clini-
cally accessible and biologically relevant therapeutic targets. We propose
that antiangiogenic gene therapy with LK68 is a promising strategy for
the treatment of colorectal cancer liver metastasis.
INTRODUCTION
Colorectal carcinoma is the third leading cause of cancer-related
deaths worldwide. Most colorectal cancer patients develop metastasis
to the liver during the course of the disease. Once liver metastases
have developed, the natural course of the disease is associated with
poor prognosis, resulting in the death of 80% of patients (1).
Surgery is the primary treatment option for isolated metastases, but
only 20% to 25% of patients displaying hepatic metastases are suit-
able for resection (2), and postoperation recurrence is frequent. There-
fore, the development of a new treatment modality for liver metastasis
of colorectal cancer is urgently required.
Tumor growth essentially requires the formation of new blood
vessels (a process known as angiogenesis) to supply tumors with
nutrients and oxygen and allow the removal of waste products (3, 4).
Moreover, metastatic spread of solid tumors depends on vasculariza-
tion of the primary mass. Therefore, blockage of tumor angiogenesis
may potentially suppress both tumor growth and metastasis. In this
regard, the angiogenic process is a promising target to develop novel
therapeutic modalities for the treatment of cancer. Numerous endog-
enous antiangiogenic inhibitors, such as angiostatin and endostatin,
have been identified that display significant efficacy against a variety
of tumors in preclinical settings (5, 6).
Lipoprotein(a) is a lipoprotein particle associated with the devel-
opment of atherosclerosis and coronary heart disease (7). Lipopro-
tein(a) is structurally distinct from low-density lipoprotein due to the
presence of apolipoprotein(a) [apo(a)], which is covalently linked to
apoB-100 protein of low-density lipoprotein by a disulfide bond (8).
Apo(a) is a glycoprotein composed of multiple kringle domains and a
protease-like domain homologous to plasminogen (9). Ten types of
kringles homologous to plasminogen kringle 4, designated KIV-1 to
KIV-10, and one kringle (KV) homologous to plasminogen kringle 5
are observed in apo(a). Each KIV domain is present as a single copy,
with the exception of KIV-2, which varies in number from 3 to 42
between apo(a) alleles (10).
The kringle domain consists of approximately 80 amino acids with
conserved rigid triple disulfide bonds and appears to be an independ-
ent folding unit. Kringle domains are present in many proteins with a
surprisingly diverse array of functions, including growth factors,
proteases, and coagulation factors (hepatocyte growth factor, plasmin-
ogen, prothrombin, urokinase, and so forth). These domains are
thought to play an important role in specific protein–protein interac-
tions that provide specificity to and facilitate the regulation of their
parent proteins. Moreover, many kringle domains have been identified
as inhibitors of angiogenesis (11). Similarly, although the physiologic
role(s) of the apo(a) kringle domains has yet to be elucidated, current
evidence suggests that these domains inhibit angiogenesis in vitro (12)
and suppress tumor growth in vivo (13). Recently, we demonstrated
that cryptic apo(a) kringle domain LK68, which contains KIV-9,
KIV-10, and KV, inhibits the proliferation and migration of endothe-
lial cells in vitro (14), in part by interfering with the activation of
extracellular signal-regulated kinase 1 and 2 in endothelial cells via a
protein tyrosine phosphatase-dependent pathway (15). Systemic ad-
ministration of recombinant LK68 proteins suppresses angiogenesis-
dependent growth of human colon (HCT-15) and lung (A549) tumors
in vivo.
For antiangiogenic cancer therapy, chronic administration of anti-
angiogenic proteins is required (16) because micrometastases may
remain dormant but viable for a long period of time. In addition, the
relatively short half-life in vivo and high therapeutic doses of recom-
binant proteins pose manufacturing and economic constraints on their
widespread clinical use (17, 18). The peak/trough kinetics resulting
from bolus administration of recombinant proteins may be insufficient
to maintain prolonged therapeutic levels in the tumor mass. Antian-
giogenic gene therapy constitutes an attractive solution to overcome
these problems (19–21) because this approach ensures sustained high
levels of therapeutic molecules in situ simply via a few injections of
the necessary antiangiogenic genes.
The present study was performed to analyze the therapeutic poten-
tial of gene therapy with LK68 in the treatment of life-threatening
hepatic metastasis of colorectal cancer. Our data show that LK68
expression in colorectal cancer cells significantly suppresses hepatic
metastasis by inhibiting tumor angiogenesis, consequently improving
overall survival rates.
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MATERIALS AND METHODS
Construction of Vectors and Expression of LK68 in CT26 Cells. LK68
cDNA was amplified by polymerase chain reaction using pET11a/LK68 (14)
as the template with the following oligonucleotide primers: 5–GCGGC-
CCAGCCGGCCAAAAGCCCTGTGGTCCAGGATTGC-3 (LK68–SfiI) and
5-CCGCTCGAGTTAAGAGGATGCACAGAGAGGGATATC-3 (LK68-
XhoI). The amplified cDNA fragment spanning nucleotides 12,052 to 12,975
(9) was cloned into the corresponding sites of an expression vector, pSecTag
(Invitrogen, Carlsbad, CA). The DNA fragment containing LK68 cDNA and
the immunoglobulin  chain secretion signal was amplified by polymerase
chain reaction with primers IgkEcoRI (5-CCGGAATTCCTAGCCACCAT-
GGAGACAGACACACTCCTG-3) and LK68-XhoI, digested with EcoRI and
XhoI, and cloned into a predigested retroviral expression vector, pLXSN
(Clontech, Palo Alto, CA). The resultant plasmid, pLXSN-LK68, was used for
subsequent transient transfection into a packaging cell line (PT67) to generate
recombinant retroviruses containing the LK68 gene, using the DOSPER lipo-
somal reagent (Roche Diagnostics GmbH, Mannheim, Germany). Empty
pLXSN was additionally used as a control. CT26 cells were exposed to
retroviral vector-containing culture supernatant, and colonies of stable cells
resistant to 1 mg/mL G418 (Calbiochem, La Jolla, CA) were selected and
further characterized. CT26 cells transduced with recombinant viruses con-
taining pLXSN or pLXSN-LK68 were designated CT-Vec and CT-LK68,
respectively.
Cell Proliferation Assay. Parental (CT-Mock), CT-Vec, or CT-LK68 cells
(1  105 cells) were seeded onto 6-well culture plates in triplicate and
incubated with Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS). Cells were harvested by treatment with 0.5%
trypsin/5.3 mmol/L EDTA4Na (Life Technologies, Inc., Rockville, MD) and
resuspended in PBS, and viable cells were counted every 24 hours using the
trypan blue dye exclusion method for 5 days.
Flow Cytometry. CT-Mock, CT-Vec, or CT-LK68 cells were grown in
DMEM supplemented with 10% FBS until the cells reached 80% confluence.
The apoptosis assay was performed using the ApoAlert annexin V-fluorescein
isothiocyanate (FITC) apoptosis kit (Clontech). Briefly, cells were harvested,
and 5  105 cells were added to a 12-mm test tube. After washing twice with
annexin buffer, cells were resuspended in 5 L of annexin V/FITC solution,
incubated at 4°C for 15 minutes, and washed with annexin buffer. Propidium
iodide solution (10 L of 10 g/mL) and 190 L of annexin buffer were
added, followed by analysis with FACSCalibur apparatus (Becton Dickinson
Immunocytometry Systems, San Jose, CA). The results were processed under
CellQuest software, analyzed by dual parameter analysis for propidium iodide
staining (FL2) versus annexin V/FITC staining (FL1), and presented as dot
plots. Cells grown in the presence of 10 g/mL Taxol (Sigma, St. Louis, MO)
were used as an experimental control.
Western Immunoblotting. Confluent cultures of CT-Vec or CT-LK68
cells were incubated in PFM protein-free medium (HyClone, Logan, UT) for
72 hours on 6-well culture plates (Nalge Nunc International, Rochester, NY).
Conditioned media were harvested from each clone and concentrated using
trichloroacetic acid solution (Sigma). Concentrated proteins were separated on
a 12.5% SDS-polyacrylamide gel and transferred to nitrocellulose membranes
(Bio-Rad, Richmond, CA). After soaking for 1 hour in blocking buffer (5%
nonfat dry milk in PBS), the membrane was incubated for 1 hour with
polyclonal mouse antibodies against recombinant LK68, followed by horse-
radish peroxidase-conjugated goat antimouse IgG (KPL, Gaithersburg, MD).
Immunoreactive bands were detected using enhanced chemiluminescence
Western blotting detection reagents (Amersham Biosciences, Freiburg, Ger-
many), according to the manufacturer’s instructions. Recombinant LK68 pro-
teins produced from Chinese hamster ovary cells were used as a control.
Animals. Male BALB/c mice, 6–8 weeks of age, were purchased from
Charles River Japan, Inc. (Yokohama, Japan). Animals were maintained under
specific pathogen-free conditions. All mice were fed a commercial diet, given
water ad libitum, and subjected to a 12-hour light/12-hour dark cycle.
Animal Model for Experimental Liver Metastasis. Two groups of mice
were anesthetized intraperitoneally with 2.5% Avertin (Sigma). The spleen
was exteriorized through a left lateral flank incision. CT-Vec or CT-LK68 cells
(5  104) in 100 L of PBS were injected into spleen parenchyma using a
27-gauge needle. The peritoneum and skin were closed in two layers with
metal clips. Mice that did not display visible “paling” of the spleen and severe
bleeding were used in subsequent studies. Mice were used in survival exper-
iments (n 10 mice per group) or sacrificed at 6, 12, and 14 days (n 5 mice
per group at each time point) after tumor cell injection. Liver samples were
collected and subjected to histologic and immunohistochemical examination.
All surgical procedures and care administered to the animals were in accord-
ance with institutional guidelines.
Histology and Immunohistochemistry. Tumor-bearing livers were dis-
sected, fixed with 10% neutral buffered formalin overnight, embedded in
paraffin, and sectioned into 4-m slices. Sections were stained with hematox-
ylin and eosin (H&E) and subjected to immunohistochemical analysis. All
tissue histology and necrosis areas were analyzed by H&E staining. Sections
subjected to immunohistochemistry were cleared with xylene and rehydrated
with ethanol. Slides used to detect the von Willebrand factor (vWF) and
proliferating cell nuclear antigen (PCNA) were boiled in 0.01 mol/L citrate
buffer (pH 6.0) for 10 minutes. Endogenous peroxidase was blocked with
peroxidase blocking solution (DAKO, Carpinteria, CA) for 30 minutes. Sec-
tions were incubated overnight at room temperature with rabbit polyclonal
anti-vWF antibody (DAKO) and monoclonal anti-PCNA antibody (DAKO).
Next, samples were incubated with biotinylated goat antirabbit antibody for 30
minutes. After incubation with labeled streptavidin-biotin kit peroxidase
(DAKO), stains were visualized with chromogen Nova Red (Vector Labora-
tories, Burlingame, CA).
Terminal Deoxynucleotidyl Transferase-Mediated Nick End Labeling
Staining. Liver sections were processed in parallel for terminal deoxynucle-
otidyl transferase-mediated nick end labeling (TUNEL) using the ApopTag
Red In Situ Apoptosis Detection kit (Intergen, Purchase, NY), according to the
manufacturer’s instructions. Sections were incubated with 40 g/mL protein-
ase K for 10 minutes at 37°C to digest proteins. Intergen proprietary equili-
bration buffer was applied to sections at room temperature for 5 minutes,
followed by incubation with DNA strand break labeling solution containing
terminal deoxynucleotidyl transferase at 37°C for 1 h. Sections were washed in
stop/wash buffer at room temperature for 10 minutes, followed by three
1-minute washes with PBS. Next, sections were incubated with anti-digoxi-
genin-alkaline phosphatase (Boehringer Mannheim Corp., Indianapolis, IN) at
37°C for 30 minutes. Tissues were counterstained with nuclear fast red
(DAKO).
Statistical Analysis. Data are presented as means  SE. Statistical signif-
icance was calculated by Student’s t test, with the exception of in vivo survival
experiments, in which we used log-rank analysis of a Kaplan-Meier survival
curve. P  0.05 was statistically significant.
RESULTS
Generation of Recombinant Colorectal Cancer Cells That Ex-
press LK68. A cDNA sequence encoding human apo(a) kringles,
LK68, was genetically fused to an immunoglobulin  leader sequence
to facilitate secretion of expressed protein and subsequently cloned
into pLXSN retroviral vector to produce pLXSN-LK68, which in-
duces transgene expression under control of the Moloney murine
leukemia virus 5-long terminal repeat promoter (Fig. 1A). LK68
expression was analyzed by Western blotting of culture supernatants
prepared from transduced cells with anti-LK68 polyclonal antibody
(Fig. 1B). LK68-immunoreactive proteins with molecular masses of
50,000 to 52,000 daltons were present in the CT-LK68 supernatant,
whereas no signal was detected in supernatant fractions from CT-Vec
or parental cells (CT-Mock). The molecular mass of LK68 produced
in CT26 cells was identical to that of LK68 from Chinese hamster
ovary cells but substantially higher than that of Escherichia coli-
derived LK68 (37,000 daltons), probably due to the presence of N-
and O-linked glycosides (data not shown). The G418-resistant stable
CT-LK68 clones showed variable level of LK68 expression. The
concentration of LK68 in 72-hour conditioned medium (CM) secreted
by 1  106 cells of CT-LK68 (clone 7), showing the highest level of
LK68 expression, was 80 ng/mL. Unless otherwise stated, CT-LK68
represents CT-LK68 clone 7 in the following experiments.
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Characterization of In vitro Growth Kinetics and Apoptosis of
Genetically Modified CT26 Cells. To determine whether the expres-
sion of LK68 in CT26 cells affects cell growth, we examined the in
vitro growth kinetics of control and LK68-expressing CT26 cells by
viable cell counting. There were no significant differences in cell
growth among CT-Mock, CT-Vec, and CT-LK68 cells (Fig. 2A). In
addition, we analyzed tumor cell viability and/or apoptosis by flow
cytometry after staining CT26 cells with annexin V and propidium
iodide. Cell viability was similar between CT-LK68 and control cells,
such as CT-Mock and CT-Vec (Fig. 2B). In all cases, 97% of cells
retained viability. CT-Mock cells treated with cytotoxic agents such as
Taxol (10 g/mL) were used to define the dead cell fraction. More-
over, there was no significant clonal variation because three different
stable clones of CT-Vec or CT-LK68 revealed similar growth kinetics
and cell viability (data not shown). The results indicate that LK68
gene delivery and expression by a retroviral vector do not intrinsically
affect the growth characteristics and viability of transduced cells.
Inhibition of Endothelial Cell Migration by LK68 Derived from
CT-LK68 Cells. To analyze the antiangiogenic activity of LK68
produced by CT-LK68 cells, we performed an in vitro wound migra-
tion assay according to a previous report (14). Human umbilical vein
endothelial cells (HUVECs) migrated readily to the denuded area in
response to filtered CM prepared from CT-Vec cells (Fig. 3A). How-
ever, on treatment of HUVECs with CM from CT-LK68, an approx-
imate 50% reduction in cell migration was observed, compared with
controls (P  0.05; Fig. 3B). To determine whether the decreased
migration of HUVECs is mediated by LK68 present in CM, the
migration assay was performed in the presence of rabbit anti-LK68
antisera or preimmune rabbit sera. HUVEC migration recovered to
control levels after pretreatment with anti-LK68 antibodies
(P  0.05). In contrast, control antibodies had no influence on
migration patterns, clearly signifying that LK68 is responsible for the
observed antimigratory effects (Fig. 3B).
Suppression of Liver Metastasis after Intrasplenic Injection.
To determine the effect of LK68 expression in colorectal cancer cells
on hepatic metastasis, CT-Vec and CT-LK68 cells were injected into
the spleens of syngeneic BALB/c mice. Livers from both groups of
animals (n  5 mice per group at each time point) were collected at
postoperation day (POD) 6, 12, and 14. Macroscopically, no signifi-
cant differences were observed until POD 12 in terms of shape, size,
liver weight, and number of metastasized surface nodules. At POD 14,
control animals displayed enlarged livers covered with numerous
tumor nodules throughout and with a whitish and irregular surface
caused by extensive tumor growth, whereas livers from mice injected
with CT-LK68 cells were smaller in size, displaying a macroscopi-
cally normal appearance with a few surface nodules (Fig. 4A). The
suppressive effect on liver metastasis was somewhat proportional to
the expression levels of LK68 proteins in transduced clones (data not
shown). The number of tumor nodules on the surface of livers from
mice that received injection with CT-Vec and CT-LK68 showing the
highest expression of LK68 were 125  14 and 46  3, respectively
(P  0.001; Fig. 4B). A significant decrease in liver weight was
additionally observed (P  0.001). Specifically, the mean liver
weights were 1.78  0.22 and 1.37  0.05 g for CT-Vec- and
CT-LK68-injected mice, respectively (Fig. 4C). Moreover, similar
inhibition of liver metastasis was also observed in mice that received
intrasplenic injection with LK68-expressing LS174T human colorec-
tal cancer cells (data not shown). These results may indicate that
suppression of colorectal cancer liver metastasis by LK68 is not
specific to the CT26 cell line, but rather representative of colorectal
cancer in general.
To further characterize the antimetastatic effects of LK68, histo-
logic examination of H&E-stained liver tissues was performed. The
extent of liver metastasis was assessed in terms of number and size of
metastases. The formation of neovessels within hepatic metastases
was reported to be required for tumors to grow beyond a critical size
Fig. 2. Effects of LK68 expression on the growth and viability of CT26 cells in vitro.
A. CT-Mock, CT-Vec, or CT-LK68 cells were incubated in DMEM supplemented with
10% FBS, and the numbers of viable cells over 5 days were counted using the trypan blue
dye exclusion method. Results are representative of three separate experiments
(mean  SE). B. CT-Mock, CT-Vec, or CT-LK68 cells were grown in DMEM supple-
mented with 10% FBS and stained with annexin V/FITC and propidium iodide. Apoptosis
was analyzed by flow cytometry, as described in Materials and Methods. FL1 on the Y
axis and FL2 on the X axis represent annexin V/FITC staining and propidiun iodide
staining, respectively.
Fig. 1. Construction of a LK68 vector and expression of the protein in CT26 cells. A,
schematic representation of the retroviral expression vector pLXSN-LK68. A truncated
apo(a) kringle domain containing KIV-9, KIV-10, and KV (designated LK68) is depicted
in gray boxes. LK68 constitutes the amino acid residues of apo(a) from Lys4003 to Ser4310.
Two predicted N-glycosylation sites (Asn4083 and Asn4197) are depicted. Black arrow, the
5-long terminal repeat promoter derived from the Molony murine leukemia virus. , the
retroviral packaging signal. Igk, immunoglobulin  leader sequence. B, Western blot
displaying LK68 expression. Lane 1, LK68 produced from E. coli; Lane 2, CM from
CT-Mock; Lane 3, CM from CT-Vec; Lane 4, CM from CT-LK68; Lane 5, LK68
produced from Chinese hamster ovary cells. Molecular mass markers are shown on the
right.
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(200 m in diameter; ref. 22). On the other hand, it was reported that
tumors below 1 mm in diameter are supplied sufficient nutrients by
diffusion (23). In view of this finding, we graded metastases sizes into
three levels, specifically, small (200 m in diameter), medium (200
m to 1 mm in diameter), and large (1 mm in diameter), represent-
ing prevascular metastases, metastases in progression to a vascular-
ized state, and macroscopic vascularized metastases, respectively.
Relatively few metastases were observed in both groups of animals at
POD 6 and POD 12. However, a significant increase in total metas-
tasis number was detected in livers from control animals at POD 14,
compared with livers bearing CT-LK68 cells (P  0.001; Fig. 5A).
The sizes of liver metastases were substantially enlarged in a time-
dependent manner in control organs. Livers containing CT-LK68 cells
were mainly occupied by small-sized metastases at all time points
(Fig. 5). The results collectively indicate that expression of LK68
affects the hepatic metastasis of colorectal cancer cells, primarily at
the level of angiogenesis-dependent growth of micrometastases.
Suppression of Tumor Angiogenesis and Induction of Tumor
Apoptosis in Liver Metastases Generated by LK68-Expressing
Colorectal Tumor Cells. To investigate the mechanism of LK68-
mediated inhibition of liver metastasis in vivo, liver samples isolated
at POD 14 were examined histologically and immunohistochemically
for tumor cell proliferation, apoptosis, and angiogenesis. Histologic
examination of H&E-stained liver tissues revealed that very large
areas of the liver contained metastases in controls bearing CT-Vec
cells, compared with those containing CT-LK68 cells (Fig. 6A and B).
Tumor cell proliferation and apoptosis were examined by immuno-
staining tissue sections using antibodies against PCNA (Fig. 6C and
D) and in situ labeling of fragmented DNA in apoptotic cells using
TUNEL technique (Fig. 6E and F), respectively. The proliferative
index and apoptotic index were determined by counting the number
of positive cells in liver metastases, which were expressed as a
percentage of total cells. Proliferative indices were similar in liver
metastases generated by CT-Vec (64.35  1.96%) and CT-LK68
(64.52  3.27%; Fig. 7A). Interestingly, apoptotic indices were sig-
nificantly increased in liver metastases generated by CT-LK68
(5.37  3.33%), compared with CT-Vec (0.48  0.47%; P  0.001;
Fig. 3. Inhibition of HUVEC migration by LK68. Confluent HUVECs were scraped
and incubated with CM from CT-LK68 in the presence of either rabbit anti-LK68 antisera
or preimmune control sera, and migration of HUVECs into the denuded area was
monitored over 8 hours. CM from CT-Vec was used as a control. A, representative
photomicrographs of migrated cells. The dotted lines indicate the area occupied by the
initial wound. B. Cells that migrated to the denuded area were counted and expressed as
percentage of migrated cells treated with CM from CT-Vec. Results are representative of
three separate experiments (means  SE). , P  0.05.
Fig. 4. Macroscopic evaluation of the effects of LK68 expression in CT26 cells on liver
metastasis. CT-Vec and CT-LK68 cells were injected into the spleens of BALB/c mice.
Fourteen days later, mice were sacrificed, and liver metastases were examined. A,
representative photograph showing livers obtained from mice that received injection with
CT-Vec and CT-LK68, as indicated. Scale bar, 1 cm. B and C, quantitative analysis of the
number of surface tumor nodules and weights of tumor-bearing livers from mice that
received injection with CT-Vec and CT-LK68 cells. These experiments were repeated
three times with similar results. Data are expressed as means  SE.
Fig. 5. Histologic examination of the effect of LK68 expression on the number and size
of liver metastases. Mice received intrasplenic injection with CT-Vec (f) or CT-LK68
() cells. Livers were isolated at 6, 12, and 14 days after tumor cell administration, and
histologic examination of H&E-stained tissue sections was performed. A, quantitative
analysis of the total number of metastases in tumor-bearing livers. B	D, distribution of
the sizes of metastases in livers at 6 (B), 12 (C), and 14 days (D) after tumor cell
administration. Metastatic foci were subdivided into three groups according to diameter:
small (S), 200 m; medium (M), 200 m to 1 mm; large (L), 1 mm. , P  0.0005.
, P  0.0001.
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Fig. 7B). There were no significant effects on proliferation and apo-
ptosis in the normal regions of liver tissues from both groups of mice,
indicating that intratumoral expression of LK68 is not toxic to normal
liver tissues. We immunostained tumor-bearing liver tissues with an
endothelial-specific antibody raised against vWF to determine the
effects of LK68 expression on tumor angiogenesis (Fig. 6G and H). A
significant reduction in the number of vWF-positive blood vessels
was observed in LK68-expressing liver metastases, compared with
control tumors (Fig. 7C; P  0.001). The results indicate that LK68
expression in colorectal cancer cells reduces angiogenesis and induces
apoptotic death of tumor cells that metastasized into the liver with no
toxicity to normal liver tissues.
Extension of Survival by LK68 Gene Delivery. To analyze
whether the suppression of liver metastasis by LK68 expression
prolongs overall survival, mice (n  10 mice per group) received
intrasplenic injection with CT-Vec or CT-LK68 cells, and the fraction
of surviving animals was monitored over time. As depicted in Fig. 8,
host survival was significantly improved in animals bearing CT-LK68
cells, compared with control animals (log-rank test, P  0.001). The
median survival was 24.5 and 35 days for groups of animals injected
with CT-Vec and CT-LK68 cells, respectively. Our data collectively
indicate that inhibition of hepatic metastasis of colorectal cancer cells
by LK68 gene delivery leads to substantial extension of survival.
DISCUSSION
Antiangiogenesis therapy is a promising treatment for cancer,
based on the finding that most tumors and their metastasis are
angiogenesis dependent. Gene therapy can potentially expand the
horizons of tumor angiogenesis therapy due to the production of
high concentrations of therapeutic agents within a local area for a
sustained period. Antiangiogenic gene therapy with angiostatin
(24) or endostatin (25) induces significant anti-metastasis effects,
supporting its potential use for the treatment of colorectal cancer
metastatic to liver. Moreover, the idea that blocking angiogenesis
is an effective strategy to treat human metastatic colorectal cancer
can be further validated by the recent approval of bevacizumab
(Avastin), a humanized monoclonal antibody against vascular en-
dothelial growth factor, by the United States Food and Drug
Administration as a first-line therapy for metastatic colorectal
cancer. In the present study, we show that expression of LK68 in
colorectal cancer cells substantially suppresses hepatic metastasis
and has statistically significant survival advantages in animals,
indicating that LK68 cDNA is a promising candidate as a gene
therapy agent to treat hepatic metastasis of colorectal cancer.
Fig. 6. Histologic and immunohistochemical examination of proliferation, apoptosis,
and angiogenesis in tumors. Representative photomicrographs of tumor tissues from mice
that received injection with CT-Vec (A, C, E, and G) or CT-LK68 cells (B, D, F, and H)
are shown. A and B. Sections of tumor tissue were stained with H&E. Magnification,40.
Scale bar, 200 m. C and D. Tumor cell proliferation was determined by immunostaining
of tumor tissues with anti-PCNA antibodies. Magnification, 400. E and F. Tumor cell
apoptosis was examined by labeling fragmented DNA using TUNEL. Magnification,
400. Apoptotic cells are indicated by arrows. G and H. Immunostaining of tumor tissues
using an antibody against vWF is depicted. Magnification, 200.
Fig. 7. Quantitative analysis of proliferation, apoptosis, and angiogenesis. A. The cell
proliferative index was measured by counting cells stained with anti-PCNA antibody and
expressed as a percentage relative to the total number of cells. B. The apoptotic index was
measured by labeling fragmented DNA in apoptotic cells using TUNEL, counting cells,
and expressing values as percentages relative to the total number of cells. A and B.
Approximately 2,000 cells were counted at a magnification of 400. The values in each
column represent means  SE. C. Tumor tissues were immunostained with anti-vWF
antibodies, and blood vessels in at least 10 random high-power fields were counted. Each
column represents means  SE.
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Angiogenesis is the net result of a dynamic balance between
proangiogenic and angiostatic factors in the extracellular microen-
vironment of a tumor (26). Expression of LK68 in tumors may
either increase the local concentrations of angiogenesis inhibitors
or decrease the expression of angiogenic factors, such as angio-
genin, basic fibroblast growth factor, and vascular endothelial
growth factor (14), and consequently shifts the balance between
angiogenesis and antiangiogenesis in favor of the latter, leading to
suppression of tumor angiogenesis. This theory was confirmed by
histologic and immunohistochemical findings showing that in
LK68-expressing colorectal cancer liver metastases, microvessel
density was substantially decreased and metastases were restricted
to sizes smaller than 200 m in diameter. Notably, angiogenesis
is required for liver metastases to grow beyond this size (22).
Therefore, LK68 appears to suppress hepatic metastasis of colo-
rectal cancer by inhibiting the development of new vasculatures in
liver metastases, thus limiting the progression of prevascular mi-
crometastases to a vascularized state and growth of vascularized
metastases. Similarly, systemic administration of the angiogenesis
inhibitor endostatin has been reported to inhibit the generation of
hepatic micrometastases and macrometastases growth of colorectal
cancer cells (27).
Expression of LK68 in colorectal cancer cells did not affect the
growth kinetics and viability of cancer cells in vitro. However, inter-
estingly, tumor cell apoptosis was considerably increased in LK68-
expressing liver metastases in vivo, whereas no significant effects on
tumor cell proliferation were observed. Similar results were observed
in metastatic liver cancer treated by either gene transfer using adeno-
associated virus vector encoding angiostatin (24) or a small molecule
inhibitor of vascular endothelial growth factor receptor, SU5416 (28).
The mechanism of induction of tumor cell apoptosis is currently
unclear, but it appears to be associated with the inhibition of tumor
angiogenesis by LK68, which may limit the supply of oxygen and
nutrients to tumor cells. When the loss of adequate vasculature occurs,
tumor cells supported by these vessels subsequently undergo apopto-
sis. Several studies show that angiogenesis inhibitors induce tumor
cell apoptosis by decreasing the levels of paracrine tumor cell survival
factors derived from endothelial cells, such as platelet-derived growth
factor, interleukin 6, and heparin-binding epithelial growth factor,
among others (29). However, the issue of whether LK68 directly
inhibits the production of these paracrine factors by endothelial cells
remains to be elucidated.
Metastasis is a highly selective and nonrandom process that con-
sists of a series of steps, including escape of cells from a primary
tumor into the blood or lymphatic circulation (intravasation), survival
of cells in the circulation, arrest in a secondary organ, escape from
circulation into the surrounding tissue (extravasation), initiation and
maintenance of growth, and vascularization of the metastatic tumor
(30, 31). Any of these phases of metastasis may be a therapeutic target
because the failure of any one step disrupts the entire metastatic
cascade.
By the time primary colorectal cancers are detected, subclinical or
clinically relevant liver metastases have already occurred (32). Thus,
later steps offer more promising targets for therapy because these may
not have occurred at the time of colorectal cancer diagnosis. Recent
studies demonstrate that cancer cell arrest and survival in the micro-
circulation and the extravasation process are performed with very high
efficiency (33, 34), whereas the initiation of growth to form micro-
metastases and formation of macroscopic metastases are considerably
less efficient. Targeting an inefficient biological process is easier than
targeting an efficient one because fewer cells are inhibited. In view of
these considerations, antiangiogenesis therapy using LK68, which
primarily targets the angiogenesis-dependent growth of metastasis, is
a clinically accessible and biologically relevant therapeutic strategy
for liver metastasis.
Two general strategies of antiangiogenic gene therapy have been
proposed, specifically, tumor-directed gene therapy and systemic gene
therapy. Because antiangiogenesis therapy displays a low toxicity
profile and is designed to treat both tumor metastasis and growth,
almost all therapeutic approaches to date have been systemic in
nature. However, in the treatment of colorectal cancer metastatic to
liver, tumor-directed, regional administration of angiostatic genes is
advantageous because this ensures maximal levels of transgenic pro-
teins in situ and minimal systemic toxicity, compared with systemic
gene delivery. Moreover, the unique anatomic features of the liver
facilitate regional treatment approaches (35).
As antiangiogenic drugs are directed against components of the
developing vasculature, they may lead to stable disease rather than
complete remission and have little or no effect on bulky end-stage
tumors. Moreover, discontinuation of antiangiogenic therapy may
allow the tumor or its metastases to resume growth (36–38). Hence,
the patients most suitable for long-term antiangiogenic treatment are
possibly those with “early metastatic” or “minimal residual” disease,
such as the growth of dormant metastases occurring after surgical
removal of a primary tumor (5, 39) or following the reduction of the
primary tumor by ionizing radiation (40). The experimental model
used in this study is appropriate for this patient category. In this
setting, therapeutic antiangiogenesis may prolong the state of tumor
dormancy by suppressing micrometastases that remain despite suc-
cessful treatment of primary tumors.
Although antiangiogenic therapy using LK68 induces dormancy of
micrometastases, complete eradication of dormant tumor cells that
exist in the form of either nonproliferating solitary cells or preangio-
genic micrometastases was not accomplished in this study. These
dormant cells pose a substantial future danger of metastasis recur-
rence. Accordingly, a combination of antiangiogenic therapy and
conventional chemotherapy (41, 42) or radiotherapy (43) is an appro-
priate clinical approach. Such a combination with anti-growth thera-
pies may improve suppressive effects because they directly target the
growth of tumor cells, leading to remission of metastases and tumor
cell eradication.
Our data clearly show that LK68 cDNA is a promising candidate
for antiangiogenic gene therapy. In parallel with the development of
gene delivery systems that present therapeutic genes specifically and
efficiently to the tumor site, future application of antiangiogenic gene
therapy with LK68 in clinical settings may provide an efficient way to
treat colorectal cancer metastatic to the liver.
Fig. 8. Kaplan-Meier survival curve of mice bearing liver metastases. Two groups of
mice (n  10 mice per group) received intrasplenic injection with CT-Vec or CT-LK68
cells, and the fraction of surviving mice was monitored over time. Differences in survival
were statistically significant, as determined by log-rank analysis (P  0.001).
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